KFDA approves another indication for Enbrel
Published: 2004-11-05 06:57:00
Updated: 2004-11-05 06:57:00
Wyeth Korea said the Korea. Food and Drug Administration approved Enbrel in October 28 to treat severe ankylosing spondylitis (AS). The drug, marketed by Amgen and Wyeth Pharmaceuticals, is already approved to treat rheumatoid arthritis.
Enbrel is the first biologic drug approved to treat the ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
